816 filings
Page 3 of 41
8-K
w38udrl1ez ec49
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
rlf9cj ye9ur
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
2fvobuyw2c2opwlzk23
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
58jh3xeju09l8zwktv58
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
EFFECT
97t55s 5dzu
8 May 23
Notice of effectiveness
12:15am
424B4
iyisbl9n 0z7yf3
5 May 23
Prospectus supplement with pricing info
6:43pm
CORRESP
2gk m0vp3c192
4 May 23
Correspondence with SEC
12:00am
8-K
wgab vinp
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
gk6go5cow9x5 5s6
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am
8-K
gemg6z988ey1q b6d
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
huam3d vgksrc49rzt
19 Apr 23
Correspondence with SEC
12:00am
8-K
p0x80tzbnfcejjfzu
14 Apr 23
Other Events
8:33am
8-K
tb9m sc2u0x66
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
UPLOAD
bfy frilkdpo9e4
7 Apr 23
Letter from SEC
12:00am
8-K
cjlx90
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm